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Stereotactic radiosurgery (SRS), coupling radiation 
with a stereotactic guiding device, was first performed by 
Leksell in 1951 [1]. SRS is now an established treatment 
option for many benign and malignant tumours. With the 
advances  in  technology,  including  patient/target 
immobilisation, tumour/target tracking, image-guidance, 
and radiation planning and delivery, SRS to extracranial 
sites  has  become  a  reality.  Extracranial  stereotactic 
radiosurgery/radioablation or stereotactic body radiation 
therapy (SBRT) is defined by the American Society for 
Therapeutic Radiology and Oncology (ASTRO) and the 
American College of Radiology (ACR) as a “treatment 
method to deliver a high dose of radiation to the target, 
utilising  either  a  single  dose  or  a  small  number  of 
fractions with a high degree of precision within the body 
[2].”  
Like  any  novel  therapeutic  approach  in  medicine, 
SBRT needs to be performed with caution and ideally in 
the  clinical  trial  setting,  especially  in  view  of  the 
biologically potent dose prescription as high as 20 to 30 
Gy per fraction. Practice guidelines should be followed 
to avoid the risk of severe complications [2]. Teamwork 
is essential for the success of this new treatment, and the 
team should include not only medical physicists, but also 
dosimetrists,  radiation  therapists,  nurses,  radiologists, 
and  radiation  oncologists.  Some  essential  components 
needed for the clinical implementation of SBRT include: 
patient  immobilisation  and  accurate  reposition  from 
simulation session to each treatment session, accounting 
for  motion  or  tracking  “moving  target”  e.g.,  lung 
tumours, fusion of various imaging studies, construction 
of  tight  dose  distributions  covering  tumour  with  rapid 
fall-off  the  adjacent  normal  tissues,  as  well  as  the 
availability of image-guidance. The article in this issue 
of  Biomedical  Imaging  and  Intervention  Journal  [3] 
illustrates the proper conduct of SBRT, which includes 
the use of immobilisation device, accurate repositioning 
of the patient with KV-X Ray as image-guidance, 4D-CT 
to account for tumour motion, proper fusion of PET/CT 
and  MRI  with  simulation  CT,  use  of  visicoil/bony 
landmarks for image-guidance, and construction of tight 
isodose around the tumour. 
Radiobiologically, the dose fraction regimens used 
in  SBRT  ranging  from  6  to  30Gy,  are  aimed  to  yield 
substantially more potent biological and clinical effects. 
Applying  linear-quadratic  formula,  Fowler  and 
colleagues  have  compared  the  relative  biological 
effectiveness  of  various  SBRT  fractionation  schemes 
with the conventional fractionation scheme for non-small 
cell  lung  cancer  [4].  The  conventional  60Gy  in  30 
fractions  (2  Gy  per  fraction)  and  60Gy  in  3  fractions 
(20Gy  per  fraction)  have  biological  equivalent  doses 
(BED) of 72Gy and 180Gy, respectively, as well as can 
yield an estimated progression free survival at 30 months 
of  15%  and  >99%  respectively.  Therefore,  SBRT 
approach is especially beneficial for treating more radio-
resistant  tumours,  such  as,  non-small  cell  lung  cancer, 
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melanoma, and renal cell carcinoma as illustrated by Teh 
et al [3], both in primary and metastatic settings.  
Clinical  experience  is  most  vast  in  the  three 
extracranial  sites,  namely lung, liver, and spine. Small 
non-small  cell  lung  cancers  (Stage  I  and  II)  in  either 
operable  or  medically  inoperable  patients  as  well  as 
metastatic  lung  lesions  have  been  treated  with  SBRT. 
Doses as high as 60Gy in 3 fractions were used without 
any significant complication  [4-6]. A multi-institutional 
retrospective  study  from  Japan  showed  that  patients 
treated  with  SBRT  have  a  similar  survival  when 
compared  to  patients  treated  surgically,  but  with  less 
treatment-related  morbidity  [7].  Radiation  Therapy 
Oncology Group (RTOG) is currently running a Phase II 
trial addressing SBRT in early non-small cell lung cancer 
in medically inoperable patients. Similar promising local 
control  and  favourable  toxicity  profiles  were  achieved 
using SBRT in primary hepato-cellular carcinoma (HCC) 
and metastatic liver lesions [8-10]. SBRT or SRS to the 
spine enables re-treatment after the initial conventional 
fractionated radiotherapy. Special attention needs to be 
paid to the spinal cord, especially in previously irradiated 
patients.  Again,  the  local  control  rates,  including  pain 
relief  with  SBRT,  have  been  very  satisfactory  with 
minimal  side-effects  [11-13].  Similar  results  were 
reported by Teh et al in this issue of biij [3]. 
SBRT  is  an  emerging  treatment  paradigm  with  a 
new  promise  in  radiation  oncology.  The  promise  to 
produce biologically potent dose in a shorter period of 
time and a non-invasive manner is very attractive. SBRT 
can also be applied to patients with metastatic disease for 
cyto-reduction  in  combination  with  chemotherapy  and 
for  more  durable  and  faster  symptoms  palliation. 
Nevertheless,  many  aspects  of  SBRT  need  further 
investigations  and  research.  What  is  the  best  SBRT 
fractionation scheme? Is the best scheme dependent on 
cancer type, organ site, tumour size, degree of hypoxia, 
etc?  Many  other  radiobiological  questions  also  need 
answers,  e.g.,  the  optimal  radiobiological  model  for 
tumour and normal tissues when treated with SBRT and 
the mechanism of SBRT in overcoming radio-resistance. 
Clinically, besides patient’s symptoms evaluation, there 
is still debate on the best imaging modality for follow-up 
as one can still see the stable tumour mass on CT for 
some time post-treatment. Functional biological imaging 
like  PET/CT  may  be  better  than  the  conventional 
anatomic imaging. Future work should also look into the 
effects  of  SBRT  in  combination  with  novel  targeted 
agents, such as, EGFR-inhibitor and VEGF-inhibitor. 
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